FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077183730> ?p ?o ?g. }

• W2077183730 endingPage "1109" @default.
• W2077183730 startingPage "1099" @default.
• W2077183730 abstract "Progressive or higher-risk myelodysplastic syndrome (MDS) is often treated with intensive chemotherapy regimens used for acute myelogenous leukemia (AML). Patients with MDS are often older and may have contraindications to anthracycline-based regimens. Topotecan-cytarabine regimens have shown encouraging results in higher-risk MDS. The aim of this study was to analyze the long-term results with topotecan-cytarabine versus other intensive chemotherapy regimens in higher-risk MDS.Five hundred ten patients with higher-risk MDS treated with intensive chemotherapy were reviewed. Their median age was 63 years; 82% had intermediate 2 or high-risk MDS; 32% had secondary MDS; 40% had chromosome 5 or 7 abnormalities. Therapy was: topotecan-cytarabine in 77; idarubicin-cytarabine regimens in 270; topotecan-cytarabine and cyclophosphamide in 67; fludarabine-cytarabine in 96. Univariate and multivariate analyses were conducted to evaluate the independent associations of different variables, and most important, the treatment regimen, with complete response, induction mortality, and survival.The overall complete response (CR) rate was 55%, induction mortality 17%, and 5-year survival rate 8%. The 5-year survival rate was 11% for patients younger than 65 years old and 17% for patients with a normal karyotype. Among 82 patients younger than 65 years with a normal karyotype, the CR rate was 67%, 5-year survival rate 27%, and 5-year CR duration rate 33%. Topotecan-cytarabine regimens were equivalent to idarubicin-cytarabine regimens in relation to CR rates and survival rates, but were associated with a lower induction mortality. Multivariate analysis confirmed that treatment regimens were not associated with independent significant differences in CR rates or survival. However, topotecan-cytarabine regimens were still selected to be associated with lower induction mortality rates.This analysis suggests that topotecan-cytarabine regimens are equally effective to other AML regimens in higher-risk MDS and may be less toxic. Topotecan-cytarabine may be considered a reasonable alternative to idarubicin-cytarabine in higher-risk MDS, particularly in older patients with contraindications to anthracyclines." @default.
• W2077183730 created "2016-06-24" @default.
• W2077183730 creator A5006104041 @default.
• W2077183730 creator A5014102823 @default.
• W2077183730 creator A5015101485 @default.
• W2077183730 creator A5027575595 @default.
• W2077183730 creator A5036290225 @default.
• W2077183730 creator A5057920623 @default.
• W2077183730 creator A5059555096 @default.
• W2077183730 creator A5061285204 @default.
• W2077183730 creator A5085991502 @default.
• W2077183730 creator A5090435894 @default.
• W2077183730 date "2006-01-24" @default.
• W2077183730 modified "2023-10-17" @default.
• W2077183730 title "Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome" @default.
• W2077183730 cites W146134068 @default.
• W2077183730 cites W1501742295 @default.
• W2077183730 cites W1504303645 @default.
• W2077183730 cites W1514782697 @default.
• W2077183730 cites W1535095237 @default.
• W2077183730 cites W1580063028 @default.
• W2077183730 cites W1814791463 @default.
• W2077183730 cites W187238933 @default.
• W2077183730 cites W1879966002 @default.
• W2077183730 cites W1963846089 @default.
• W2077183730 cites W1974804829 @default.
• W2077183730 cites W1979820704 @default.
• W2077183730 cites W1979998638 @default.
• W2077183730 cites W1996887331 @default.
• W2077183730 cites W2002226188 @default.
• W2077183730 cites W2007386979 @default.
• W2077183730 cites W2027178014 @default.
• W2077183730 cites W2033556677 @default.
• W2077183730 cites W2035523033 @default.
• W2077183730 cites W2037576870 @default.
• W2077183730 cites W2041965576 @default.
• W2077183730 cites W2061960126 @default.
• W2077183730 cites W2064698668 @default.
• W2077183730 cites W2071287509 @default.
• W2077183730 cites W2084329775 @default.
• W2077183730 cites W2102776788 @default.
• W2077183730 cites W2106292925 @default.
• W2077183730 cites W2106584820 @default.
• W2077183730 cites W2117291755 @default.
• W2077183730 cites W2117327010 @default.
• W2077183730 cites W2129975746 @default.
• W2077183730 cites W2131639268 @default.
• W2077183730 cites W2167734044 @default.
• W2077183730 cites W2168387971 @default.
• W2077183730 cites W2172104048 @default.
• W2077183730 cites W2539406506 @default.
• W2077183730 cites W2555604314 @default.
• W2077183730 cites W2569237377 @default.
• W2077183730 cites W4242752547 @default.
• W2077183730 cites W4251499182 @default.
• W2077183730 cites W4253916874 @default.
• W2077183730 cites W4293241248 @default.
• W2077183730 cites W4376542879 @default.
• W2077183730 doi "https://doi.org/10.1002/cncr.21699" @default.
• W2077183730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16435387" @default.
• W2077183730 hasPublicationYear "2006" @default.
• W2077183730 type Work @default.
• W2077183730 sameAs 2077183730 @default.
• W2077183730 citedByCount "96" @default.
• W2077183730 countsByYear W20771837302012 @default.
• W2077183730 countsByYear W20771837302013 @default.
• W2077183730 countsByYear W20771837302014 @default.
• W2077183730 countsByYear W20771837302015 @default.
• W2077183730 countsByYear W20771837302016 @default.
• W2077183730 countsByYear W20771837302017 @default.
• W2077183730 countsByYear W20771837302018 @default.
• W2077183730 countsByYear W20771837302019 @default.
• W2077183730 countsByYear W20771837302020 @default.
• W2077183730 countsByYear W20771837302021 @default.
• W2077183730 countsByYear W20771837302022 @default.
• W2077183730 countsByYear W20771837302023 @default.
• W2077183730 crossrefType "journal-article" @default.
• W2077183730 hasAuthorship W2077183730A5006104041 @default.
• W2077183730 hasAuthorship W2077183730A5014102823 @default.
• W2077183730 hasAuthorship W2077183730A5015101485 @default.
• W2077183730 hasAuthorship W2077183730A5027575595 @default.
• W2077183730 hasAuthorship W2077183730A5036290225 @default.
• W2077183730 hasAuthorship W2077183730A5057920623 @default.
• W2077183730 hasAuthorship W2077183730A5059555096 @default.
• W2077183730 hasAuthorship W2077183730A5061285204 @default.
• W2077183730 hasAuthorship W2077183730A5085991502 @default.
• W2077183730 hasAuthorship W2077183730A5090435894 @default.
• W2077183730 hasBestOaLocation W20771837301 @default.
• W2077183730 hasConcept C126322002 @default.
• W2077183730 hasConcept C141071460 @default.
• W2077183730 hasConcept C143998085 @default.
• W2077183730 hasConcept C2776283816 @default.
• W2077183730 hasConcept C2776694085 @default.
• W2077183730 hasConcept C2778041864 @default.
• W2077183730 hasConcept C2779117419 @default.
• W2077183730 hasConcept C2780007613 @default.
• W2077183730 hasConcept C2780817109 @default.
• W2077183730 hasConcept C2781209748 @default.

• next